首页 > 最新文献

B15. IMMUNOTHERAPY FOR LUNG DISEASE最新文献

英文 中文
Benralizumab for Chronic Obstructive Pulmonary Disease: Results of the Phase III GALATHEA Trial Benralizumab治疗慢性阻塞性肺疾病:III期GALATHEA试验结果
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2626
G. Criner, B. Celli, C. Brightling, A. Agustí, A. Papi, F. Sciurba, D. Sin, C. Vogelmeier, M. Kato, V. Shih, M. Jison, P. Newbold, M. Goldman, U. Martin
{"title":"Benralizumab for Chronic Obstructive Pulmonary Disease: Results of the Phase III GALATHEA Trial","authors":"G. Criner, B. Celli, C. Brightling, A. Agustí, A. Papi, F. Sciurba, D. Sin, C. Vogelmeier, M. Kato, V. Shih, M. Jison, P. Newbold, M. Goldman, U. Martin","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2626","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2626","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125349591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dupilumab Reduces Severe Exacerbations and Improves Lung Function Regardless of Baseline Bronchodilator Reversibility in Patients with Uncontrolled Moderate-to-Severe Asthma Enrolled in the LIBERTY ASTHMA QUEST Study 在LIBERTY Asthma QUEST研究中,Dupilumab可降低中重度哮喘患者的严重恶化并改善肺功能,无论基线支气管扩张剂可逆性如何
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2624
I. Pavord, M. Castro, K. Rabe, N. Hanania, A. Papi, J. Fitzgerald, M. Rice, P. Rowe, Y. Lu, N. Amin, H. Staudinger, N. Graham, A. Teper
{"title":"Dupilumab Reduces Severe Exacerbations and Improves Lung Function Regardless of Baseline Bronchodilator Reversibility in Patients with Uncontrolled Moderate-to-Severe Asthma Enrolled in the LIBERTY ASTHMA QUEST Study","authors":"I. Pavord, M. Castro, K. Rabe, N. Hanania, A. Papi, J. Fitzgerald, M. Rice, P. Rowe, Y. Lu, N. Amin, H. Staudinger, N. Graham, A. Teper","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2624","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2624","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"349 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114075928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Dose-Ranging Study (TERRANOVA) of Benralizumab for Moderate to Severe Chronic Obstructive Pulmonary Disease Benralizumab治疗中重度慢性阻塞性肺疾病的剂量范围研究(TERRANOVA
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2625
B. Celli, G. Criner, D. Singh, M. Bafadhel, V. Backer, A. Ramírez-Venegas, Y.-F. Wei, L. Bjermer, V. Shih, S. O'Quinn, Natalya Makulova, P. Newbold, M. Goldman, U. Martin
{"title":"A Dose-Ranging Study (TERRANOVA) of Benralizumab for Moderate to Severe Chronic Obstructive Pulmonary Disease","authors":"B. Celli, G. Criner, D. Singh, M. Bafadhel, V. Backer, A. Ramírez-Venegas, Y.-F. Wei, L. Bjermer, V. Shih, S. O'Quinn, Natalya Makulova, P. Newbold, M. Goldman, U. Martin","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2625","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2625","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129696453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis 托珠单抗治疗早期系统性硬化症的3期随机对照试验中观察到肺功能的保存
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2627
D. Khanna, Celia J. F. Lin, J. Goldin, G. Kim, M. Kuwana, Y. Allanore, A. Batalov, I. Butrimienė, P. Carreira, M. Matucci-Cerinic, O. Distler, D. Kaliterna, C. Mihai, M. Mogensen, M. Olesińska, J. Pope, G. Riemekasten, T. Rodríguez-Reyna, M. Santos, J. Laar, H. Spotswood, J. Siegel, A. Jahreis, D. Furst, C. Denton
{"title":"Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis","authors":"D. Khanna, Celia J. F. Lin, J. Goldin, G. Kim, M. Kuwana, Y. Allanore, A. Batalov, I. Butrimienė, P. Carreira, M. Matucci-Cerinic, O. Distler, D. Kaliterna, C. Mihai, M. Mogensen, M. Olesińska, J. Pope, G. Riemekasten, T. Rodríguez-Reyna, M. Santos, J. Laar, H. Spotswood, J. Siegel, A. Jahreis, D. Furst, C. Denton","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2627","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2627","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"47 18","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114100047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The Placebo Response on Lung Function in Recent Clinical Trials of Asthma Biologics 近期哮喘生物制剂临床试验中安慰剂对肺功能的影响
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2628
M. Chen, Marco Peters, B. Yoo, C. Holweg, C. Lew
{"title":"The Placebo Response on Lung Function in Recent Clinical Trials of Asthma Biologics","authors":"M. Chen, Marco Peters, B. Yoo, C. Holweg, C. Lew","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2628","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2628","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133020689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Oral TORC1 Inhibitor Dactolisib Enhances Immune Function and Reduces the Incidence of Respiratory Tract Infections in Elderly Subjects with Asthma 口服TORC1抑制剂Dactolisib增强老年哮喘患者的免疫功能并降低呼吸道感染的发生率
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2623
J. Mannick, S. Shergill, G. Teo
{"title":"Oral TORC1 Inhibitor Dactolisib Enhances Immune Function and Reduces the Incidence of Respiratory Tract Infections in Elderly Subjects with Asthma","authors":"J. Mannick, S. Shergill, G. Teo","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2623","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2623","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116293882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial Tezepelumab对严重未控制哮喘患者住院和急诊就诊的影响:来自Pathway 2b期试验的结果
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2622
J. Corren, Stephanie Chen, L. Callan, E. G. Gil
{"title":"The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial","authors":"J. Corren, Stephanie Chen, L. Callan, E. G. Gil","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2622","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2622","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"70 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127328978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study Tezepelumab治疗对未控制的严重哮喘患者基线生物标志物年化加重率的影响:2b期途径研究
Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2621
J. Corren, E. G. Gil, J. Parnes, Tuyet-Hang Pham, J. Griffiths
{"title":"Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study","authors":"J. Corren, E. G. Gil, J. Parnes, Tuyet-Hang Pham, J. Griffiths","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2621","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2621","url":null,"abstract":"","PeriodicalId":104393,"journal":{"name":"B15. IMMUNOTHERAPY FOR LUNG DISEASE","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128714140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
期刊
B15. IMMUNOTHERAPY FOR LUNG DISEASE
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1